Abstract Number: 1439 • ACR Convergence 2024
Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class
Background/Purpose: Individuals with axial spondyloarthritis (axSpA) have a risk of fracture that is nearly double that of the general population, possibly related to chronic inflammation.…Abstract Number: 1647 • ACR Convergence 2024
Improved Fertility in Women with Rheumatoid Arthritis and a Wish to Conceive When Treated According to a Treat-to-target Approach Aimed at Remission
Background/Purpose: Time to conception, known as time to pregnancy (TTP), is prolonged in women diagnosed with RA. High rates of infertility, defined as the inability…Abstract Number: 2269 • ACR Convergence 2024
Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial
Background/Purpose: The latest European and American recommendations support tapering of biological DMARDs (bDMARDs) in patients with persistent remission or low disease activity. Most clinicians use…Abstract Number: 2286 • ACR Convergence 2024
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), including those treated with disease-modifying antirheumatic drugs, high rheumatoid factor (RF) levels are a poor prognostic factor,…Abstract Number: 2358 • ACR Convergence 2024
Integration of Single-cell Multi-omics Profiling for Investigating Treatment Response to Tumor Necrosis Factor Alpha Inhibitors in Patients with Axial Spondyloarthritis
Background/Purpose: In cases where patients continue to experience active symptoms despite receiving maximum doses of nonsteroidal anti-inflammatory drug therapy in patients with axial spondyloarthritis (axSpA),…Abstract Number: 2674 • ACR Convergence 2024
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States
Background/Purpose: For patients with rheumatoid arthritis (RA), current ACR guidelines recommend evaluating treatment response within 3 months of initiating a new therapy. In patients who…Abstract Number: 0465 • ACR Convergence 2024
Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays
Background/Purpose: Treatment of RA with biologic TNF inhibitors is effective in reducing disease activity and improving radiographic progression outcomes. Therapeutic drug monitoring (TDM) of adalimumab…Abstract Number: 0499 • ACR Convergence 2024
PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment
Background/Purpose: PD-1hiCXCR5-CD4+T peripheral helper cells (Tph) are newly identified pathogenic CD4+T helper cells and participate in rheumatoid arthritis (RA) pathogenesis. However, the clinical significance of…Abstract Number: 0511 • ACR Convergence 2024
Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Background/Purpose: In pts with RA, high RF levels are associated with poor prognosis, higher disease activity, and decreased response to monoclonal antibodies targeting tumor necrosis…Abstract Number: 0871 • ACR Convergence 2024
Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”
Background/Purpose: Rheumatoid arthritis (RA) is an chronic inflammatory disease that is frequently treated with tumor necrosis factor inhibitors (TNFi). Little is known about predictors of…Abstract Number: 0989 • ACR Convergence 2024
Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis
Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…Abstract Number: 1119 • ACR Convergence 2024
Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis
Background/Purpose: Management of cardiac sarcoidosis remains controversial. Our study aimed to describe our experience using tumor necrosis factor-α-inhibitors (aTNF) in cardiac sarcoidosis treatment.Methods: This is a…Abstract Number: 1348 • ACR Convergence 2024
Analysis of Body Composition in Patients with Moderate-Severe Rheumatoid Arthritis Treated with Anti-TNF Drugs
Background/Purpose: Previous studies have described alterations in fat and lean mass in patients with RA, but the effect of treatments on body composition remains unclear.…Abstract Number: 1383 • ACR Convergence 2024
Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the proteomics profiles of patients who were inadequate responders to Etanercept (ETN-IRs) and develop an…Abstract Number: 1135 • ACR Convergence 2023
The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients
Background/Purpose: Cardiac sarcoidosis is one of the most common causes of mortality from sarcoidosis. In this retrospective study, we describe prescribing patterns and compare outcomes between patients treated with conventional immunosuppressive therapies…
- 1
- 2
- 3
- …
- 5
- Next Page »